Novavax, Inc. (NASDAQ: NVAX) shares are trading higher Tuesday after the company announced it entered into a license agreement with Pfizer, Inc. (NYSE: PFE) for use of its Matrix-M adjuvant. Under the ...

View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-reports-third-quarter-2025-financial-results-and-operational-highlights ...

Novavax faces plenty of uncertainty related to a deal it signed with a larger company. The biotech's pipeline doesn't look that exciting either. Last year, Novavax signed an agreement with Sanofi, ...

Under the non-exclusive agreement, Pfizer will utilize Novavax’s Matrix-M adjuvant in products across two disease areas, with Novavax receiving a $30 million upfront payment. Additionally, the ...

・Analysts see greater upside in Novavax, while Moderna carries a ‘Hold’ rating despite stronger gains over the past year. ・Moderna was in focus after updated cancer vaccine data, while Novavax drew ...

Vaccine biotechnology company Novavax (NASDAQ:NVAX) reported Q4 CY2025 results beating Wall Street’s revenue expectations, with sales up 66.6% year on year to $147.1 million. Its GAAP profit of $0.11 ...

Novavax, Inc. (NASDAQ:NVAX) ranks among the most oversold biotech stocks to invest in. Novavax, Inc. (NASDAQ:NVAX) announced its third-quarter 2025 financial results on November 6, emphasizing the ...

According to TipRanks.com, Hester is a 4-star analyst with an average return of 13.9% and a 50.0% success rate. Hester covers the Healthcare sector, focusing on stocks such as Telix Pharmaceuticals, ...